Quick Answer
China SXT Pharmaceuticals, Inc. reported Cash and Equivalents of $18.10 million for fiscal year 2025.
China SXT Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $18.10M | +49.9% |
| 2024 | $12.07M | -30.5% |
| 2023 | $17.37M | +30.0% |
| 2021 | $13.36M | +83.3% |
| 2020 | $7.29M | -21.6% |
| 2019 | $9.29M | +1312.6% |
| 2018 | $657.8K | +903.2% |
| 2017 | $65.6K | +473.2% |
| 2016 | $11.4K | — |
- China SXT Pharmaceuticals, Inc. showed an increase of +49.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, China SXT Pharmaceuticals, Inc.’s cash and equivalents has grown by 158122.0% (from $11.4 thousand to $18.10 million).
- The most recent figure is from China SXT Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: